Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00790569
Other study ID # CDR0000616663
Secondary ID R01CA129226BUTLE
Status Completed
Phase N/A
First received
Last updated
Start date September 2008
Est. completion date October 2012

Study information

Verified date May 2018
Source Butler Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Varenicline, the nicotine patch, and nicotine gum help people stop smoking. It is not yet known whether varenicline is more effective than the nicotine patch given together with nicotine gum in helping smokers quit smoking.

PURPOSE: This randomized clinical trial is studying varenicline to see how well it works compared with the nicotine patch given together with nicotine gum in helping smokers in a methadone treatment program stop smoking.


Description:

OBJECTIVES:

Primary

- To determine whether varenicline, a nicotine receptor partial agonist, leads to a higher rate of smoking cessation than combination nicotine replacement therapy with nicotine patch prescription plus ad libitum nicotine gum delivery in methadone-maintained smokers.

Secondary

- To test the effects of the treatments on smoking urges, withdrawal symptoms, and reinforcing effects of smoking.

- To test the effects of the treatments on methadone treatment outcomes, including retention in methadone maintenance, methadone dose changes, and continued use of illicit drugs as measured by urine toxicologies.

OUTLINE: This is a multicenter study. Patients are stratified based on gender and level of nicotine dependence. Patients are randomized to 1 of 3 intervention arms.

At baseline, all patients receive a minimal behavioral intervention using a 3-minute, simple smoking cessation counseling strategy, a self-help manual, and a telephone quit-line number.

- Arm I (varenicline): Patients receive oral varenicline once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.

- Arm II (placebo): Patients receive oral varenicline placebo once daily on days 1-3 and twice daily thereafter for a total of 6 months or when a comfortable level of smoking abstinence is reached.

- Arm III (nicotine patch/gum): Patients receive a nicotine patch, with doses tapering over time for a total of 26 weeks. Patients also receive nicotine gum to quell breakthrough urges. Patients may stop treatment when a comfortable level of smoking abstinence is reached.

Patients complete a brief interview over 10-15 minutes at 2 weeks and monthly during months 1-5. They complete a longer interview over 45 minutes at months 6 and 12 and provide breath samples (for carbon monoxide monitoring) and urine samples (for cotinine testing).

NOTE: Smoking cessation may prevent certain smoking-related illnesses, including cancer.

PROJECTED ACCRUAL: A total of 602 patients (258 receiving varenicline, 258 receiving nicotine replacement therapy, and 86 receiving placebo) will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 315
Est. completion date October 2012
Est. primary completion date October 2012
Accepts healthy volunteers No
Gender All
Age group 18 Years to 120 Years
Eligibility INCLUSION CRITERIA

- Current and regular cigarette smokers (over 10 cigarettes/day for the past 3 months)

- Interested in quitting smoking

- Willing to set a quit date 7 days after baseline assessment

- Participating in 1 of 5 methadone maintenance treatment programs across Rhode Island at any of the following institutions:

- Codac, Inc. (with two independent sites)

- Addiction Recovery Institute

- Center for Treatment and Recovery

- Discovery House

- Has received methadone for at least the past month

EXCLUSION CRITERIA

- Pregnant or nursing (Must have negative pregnancy test)

- Non-English speaking

- No personal telephone or does not live close to a relative or neighbor with a telephone

- Unwilling to make their methadone dose and methadone maintenance treatment program urine toxicologies available for review

- Unvailable for this study for the next 12 months

- Suffering from any unstable medical condition which would preclude the use of the nicotine patch (e.g., unstable angina or uncontrolled hypertension)

- Active skin condition (e.g., psoriasis)

- History of skin allergy

- History of a suicide attempt

- Working as pilots, drivers, or operators of heavy machinery

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No concurrent insulin or blood thinners

- No concurrent smokeless tobacco, nicotine replacement therapy, or other smoking cessation treatment

Study Design


Intervention

Drug:
nicotine
Given transdermally and orally
varenicline
Given orally
Other:
placebo
Given orally

Locations

Country Name City State
United States Rhode Island Hospital Comprehensive Cancer Center Providence Rhode Island

Sponsors (2)

Lead Sponsor Collaborator
Butler Hospital National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend. 2013 Dec 1;133(2):486-93. doi: 10.1016/j.drugalcdep.2013.07.005. Epub 2013 Aug 14. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Self- Reported 7-day Abstinence Number of participants with self-reported, 7-day abstinence at 6-months 6 Months
Primary Carbon Monoxide (CO)-Confirmed 7-day Abstinence Number of participants reporting 7-day abstinence at 6-months, confirmed with CO measurement. 6-Months
Primary Rates of Smoking Cessation Continuous From First Quit Day to 6 Months Number of participants who self-reported continuous abstinence from their initial quit day (study day 14) to 6 Months 6-Months
Primary Self-reported 7-day Abstinence Number of participants with self-reported 7-day abstinence at 12-months 12 Months
Primary CO-confirmed 7-day Abstinence Number of participants reporting 7-day abstinence at 12-months, confirmed with CO measurement. 12 Months
Secondary Change in Smoking Urges Smoking urges was measured on a 0 (not at all) - 100 (strongest feeling possible) scale. Higher values represent greater urge to smoke. Change in smoking urges was calculated as Follow-up score (6 month) - Baseline Score. 6 months
Secondary Withdrawal Symptoms Withdrawal Symptoms were measured using a modified version of the Minnesota Behavior Rating Scale. The scale asked subjects to rate their smoking withdrawal symptoms over the previous 24 hours on a scale from 0 (none) to 4 (severe). Higher values indicate more severe withdrawal symptoms. Change in withdrawal symptoms was calculated as Follow-up score (6 month) - Baseline Score. 6 months
Secondary Retention in Methadone Maintenance 12 months
Secondary Methadone Dose Changes 12 months
Secondary Use of Illicit Drugs as Measured by Urine Toxicologies 12 months
Secondary Reinforcing Effects of Smoking Reinforcing effects of smoking was measured using the modified version of the Cigarette Evaluation Questionnaire. Participants were asked to indicate on a 12-item scale how smoking made them feel in the prior 30 days on a scale from 1 (Not at all) to 7 (Extremely). Higher values indicated that smoking was a more positive experience for 10 of 12 items. Two items were reverse coded. Change in reinforcing effects of smoking was calculated as Follow-up score (6 month) - Baseline Score. 6 months
Secondary Change in Cigarettes Per Day Change in mean cigarettes per day 6-Months
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk